Investment Thesis
Annexon maintains a strong balance sheet with $175.2M in cash and zero debt, providing multi-year operational runway. However, operating losses of $46.1M and worsening net income deterioration of -50.9% YoY indicate accelerating cash burn without near-term revenue, creating execution risk entirely dependent on pipeline success.
Strengths
- Exceptional cash position of $175.2M with zero debt enabling operational flexibility
- Outstanding liquidity ratios (6.35x current ratio) with minimal leverage and liabilities of only $58.4M
- Strong stockholders' equity of $204.5M providing substantial financial cushion for R&D investment
Risks
- Accelerating operating losses with net income deteriorating 50.9% YoY and EPS worsening 32.7% YoY
- Pre-revenue clinical-stage company with $46.8M quarterly operating cash burn and no near-term commercialization
- Dilution risk and additional capital raise necessity as cash runway estimated at 3-4 years at current burn rate
- Pipeline success entirely dependent on clinical trial outcomes and regulatory approval with no revenue diversification
Key Metrics to Watch
- Operating cash burn rate and months of cash runway remaining
- Clinical trial enrollment and efficacy results for lead candidates
- Timing and amount of next capital raise and potential dilution impact
Financial Metrics
Revenue
N/A
Net Income
-44.1M
EPS (Diluted)
$-0.23
Free Cash Flow
-46.8M
Total Assets
262.9M
Cash
175.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-21.6%
ROA
-16.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
6.35x
Quick Ratio
6.35x
Debt/Equity
0.00x
Debt/Assets
22.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:44:38.844152 |
Data as of: 2026-03-31 |
Powered by Claude AI